NasdaqGM:SEPNPharmaceuticals
Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile?
Septerna, Inc. recently announced that CEO and co-founder Jeffrey Finer will present the company’s G protein-coupled receptor drug discovery platform at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, with a live webcast and 30-day archive available to investors.
Investor attention has also increased after Raymond James began covering Septerna with a positive view, highlighting growing institutional interest in the company’s clinical-stage...